Antimicrobials
Ceftriaxone

Ceftriaxone

High
N/A
$

Dosing

General Information

Treatment

  • Sepsis
  • Meningitis
  • Pneumonia
  • Acute otitis media
  • Rhinosinusitis
  • Skin and soft tissue infections
  • Bone and joint infections
  • Intra-abdominal infections
  • Urinary tract infections
  • Endocarditis
  • Salmonellosis and shigellosis
  • Uncomplicated gonococcal infection or pelvic inflammatory disease

Prophylaxis

  • Surgical prophylaxis
  • Bacterial endocarditis in high risk patients undergoing dental treatment
  • Peritonitis in PD patients undergoing dental treatment
  • Enterococci
  • B. fragilis
  • Pseudomonas (and other more resistant gram negatives)
  • ESBL or AmpC producing Enterobacteriaceae
  • Listeria
  • MRSA

CBC with differential, platelet count, PT, renal and hepatic function tests periodically. If using in patient < 30 days old, monitor bilirubin at baseline to ensure < 5 mg/dL.

  • Intra-abdominal infections
  • Meningitis
  • Urinary Tract Infections
  • Allergy/rash (immediate or delayed)
  • Cytopenias, eosinophilia
  • Pseudocholelithiasis

Calcium containing IV solutions:

  • May enhance the adverse/toxic effect of CefTRIAXone
  • Ceftriaxone binds to calcium forming an insoluble precipitate
  • Use of ceftriaxone is contraindicated in neonates who require treatment with IV calcium-containing solutions

IM ceftriaxone may be given with 1% lidocaine to minimize pain at injection site.

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life:

  • Neonates:
    • 1-4 days of life: 16 hours
    • 9-30 days of life: 9 hours
  • Pediatrics: 6 hours
  • Adults: 8 hours

Biliary penetration: Good (40-50% unchanged excreted in bile)

CSF penetration: Good (8-16%). Higher concentrations when meninges are inflamed

Lung penetration: Good

Urine penetration: Good (33-67% unchanged)

Route of Elimination: Unchanged in the urine (33-67%) by glomerular filtration and in feces via bile